Traditional Chinese medicine composition for treating first-grade low-middle-risk hypertension

Abstract

The traditional Chinese medicine composition is prepared from the following components in parts by mass: 6 to 12 parts of rhizoma gastrodiae, 9 to 15 parts of fried semen ziziphi spinosae, 6 to 12 parts of radix achyranthis bidentatae, 10 to 20 parts of nacre mother of pearl, 10 to 20 parts of poria with hostwood, 5 to 11 parts of fried radix paeoniae alba, 3 to 9 parts of bupleurum chinense, 3 to 9 parts of fried fructus aurantii, 2 to 8 parts of honey-fried licorice root, 2 to 8 parts of radix scutellariae and 2 to 8 parts of rhizoma pinelliae. Compared with an Androp prescription, the Androp granules have more remarkable effects in the aspects of reduction of systolic pressure, diastolic pressure and the like of a subject.

Description

TECHNICAL FIELD

[0001] The present application relates to a traditional Chinese medicine composition for treating grade 1 low-to-moderate risk hypertension. BACKGROUND

[0002] Primary hypertension is characterized by elevated arterial pressure in the systemic circulation and is one of the most common cardiovascular diseases. It is also an independent risk factor for various diseases such as coronary heart disease, stroke, and heart failure. With the increasing prevalence of hypertension, it has become a major challenge in the global public health field. Grade 1 hypertension belongs to the early stage of the disease. Epidemiological data shows that among the adult residents with diagnosed hypertension in China, about 33.9% of the patients belong to grade 1 hypertension. This type of patients has a mild degree of elevated blood pressure and is easily overlooked. At the same time, due to poor compliance with lifestyle interventions, the patient's blood pressure control is poor, which may further develop into grade 2 and grade 3 hypertension. In addition, most patients have different degrees of dizziness, headache, chest tightness, palpitations, insomnia, and other symptoms, which not only aggravate hypertension, but also greatly affect the patient's quality of life. Therefore, it is of great clinical significance to actively explore a feasible and complete treatment plan for grade 1 hypertension. SUMMARY

[0003] The main purpose of the present application is to provide a traditional Chinese medicine composition for treating grade 1 low-to-moderate risk hypertension.

[0004] The technical solution adopted by the present application to solve its technical problems is:

[0005] A traditional Chinese medicine composition for treating grade 1 low-to-moderate risk hypertension, by mass parts, comprising:

[0006] Gastrodia 6-12 parts, fried Jujube seed 9-15 parts, Huai Niuxi 6-12 parts, mother-of-pearl 10-20 parts, Fushen 10-20 parts, fried Bai Shao 5-11 parts, Bei Chaihu 3-9 parts, fried Citrus aurantium 3-9 parts, and Zhigancao 2-8 parts, Huangqi 2-8 parts, and Banxia 2-8 parts.

[0007] In a preferred embodiment, the traditional Chinese medicine composition for treating grade 1 low-to-moderate risk hypertension, by mass parts, comprises:

[0008] Gastrodia 9 parts, fried Jujube seed 12 parts, Huai Niuxi 9 parts, mother-of-pearl 15 parts, Fushen 15 parts, fried Bai Shao 8 parts, Bei Chaihu 6 parts, fried Citrus aurantium 6 parts, Zhigancao 5 parts, Huangqi 6 parts, and Banxia 6 parts.

[0009] In the present application, each 1 dose of the traditional Chinese medicine composition is equivalent to 58-128 g of raw material medicine.

[0010] In the present application, the preparation method of the traditional Chinese medicine composition for treating hypertension comprises the following steps: weighing each component according to the above quality ratio, and cleaning according to the characteristics of each raw medicine; after decocting the traditional Chinese medicine composition with water, a first decocting liquid is obtained; after separating the first decocting liquid, the remaining part including the remaining dregs and residual liquid is decocted with water again to obtain a second decocting liquid; and the first decocting liquid and the second decocting liquid are combined to obtain the traditional Chinese medicine composition.

[0011] In the present application, the traditional Chinese medicine composition is boiled with strong fire and then decocted with weak fire for 25-35 min.

[0012] In the present application, the amount of water added for decocting can be 2-10 times the volume of the traditional Chinese medicine. The volume of the first decocting liquid is 200-350 mL per dose; the volume of the second decocting liquid is 200-350 mL per dose; and 1 dose of the traditional Chinese medicine composition is equivalent to 58-128 g of raw medicine.

[0013] The present application also provides the use of the traditional Chinese medicine composition in the preparation of a medicine for treating hypertension.

[0014] Further, the dosage form of the medicine is an oral preparation.

[0015] Further, the oral preparation comprises a mixture, granules, tablets, pills or capsules.

[0016] The present application provides a traditional Chinese medicine composition for treating grade 1 low-medium risk hypertension (named Anjiang granules).

[0017] Traditional Chinese medicine is based on the concept of holism and treatment based on syndrome differentiation. In the treatment of hypertension, not only the control of blood pressure is concerned, but also the improvement of symptoms and the improvement of life quality through the regulation of yin-yang balance and blood circulation. Hypertension is mainly attributed to the category of "headache" and "dizziness" in traditional Chinese medicine. Yin deficiency and yang hyperactivity are one of the main syndromes. Academician Chen Keji believes that early hypertension is light, short in course, and shallow in location, mainly in the middle and upper two jiao, with heart and liver yin deficiency and liver yang hyperactivity. The Anjiang granules of the present application are summarized by the inventors on the basis of inheriting the academic thought of academician Chen Keji and under the guidance of the theory of "heart governing spirit", combined with their own clinical experience for more than 30 years. The whole prescription has the effects of "calming the heart and hiding the yang, regulating the qi movement". Prescription explanation:

[0018] The applicant previously applied for "Anjiang Decoction". Anjiang Decoction is made by adjusting and modifying Suanzaoren Decoction, Tianma Gouteng Decoction and Sini San. The whole prescription focuses on the core pathogenesis of early hypertension of heart-liver yin deficiency and hyperactivity of liver yang, and pays attention to the regulation of heart on the ascending and descending of qi. Suanzaoren nourishes heart and liver, and Tianma restrains liver yang, both of which are the monarch drugs; Zhenzhuomo is cold in nature and helps the monarch drugs to calm the heart and spirit, and to suppress liver yang, Baishao nourishes yin and blood to suppress liver yang, Fushen calms the heart and spirit, and also invigorates the spleen and removes phlegm, all of which are the ministerial drugs; Chaihu, Jiaoshe and Niuxi are added to make the ascending and descending of qi appropriate and to regulate the flow of qi; Gancao is combined with Baishao to make yin with acid and sweet, and also to regulate all drugs. The whole prescription has the effects of calming the heart and suppressing yang, and regulating the flow of qi. The "Anjiang Granules" of the present application is based on "Anjiang Decoction", and combined with the requirements of clinical practice and years of clinical experience, Huangqi and Banxia are added. Huangqi and Banxia are added to enhance the effect of regulating the flow of qi. It is proved by practice that the Anjiang Granules can further significantly reduce various indexes compared with Anjiang Decoction. DETAILED DESCRIPTION

[0019] Example 1

[0020] Gastrodia 9g, Fried Suanzaoren 12g, Huai Niuxi 9g, Pearl Mother 15g, Fushen 15g, Fried Baishao 8g, Beichaihu 6g, Fried Jiaoshe 6g, Fried Gancao 5g, Huangqi 6g and Banxia 6g.

[0021] Firstly, stir evenly, then soak in 300ml water for half an hour, boil with big fire, then turn to small fire and decoct for about half an hour, filter, add 300ml water to the filter residue, decoct for half an hour, mix the two filtrates after pouring out, and the daily dosage is obtained.

[0022] Example 2

[0023] Gastrodia 6g, Fried Suanzaoren 15g, Huai Niuxi 6g, Pearl Mother 20g, Fushen 10g, Fried Baishao 10g, Beichaihu 3g, Fried Jiaoshe 9g, Fried Gancao 2g, Huangqi 6g and Banxia 6g.

[0024] Firstly, stir evenly, then soak in 300ml water for half an hour, boil with big fire, then turn to small fire and decoct for about half an hour, filter, add 300ml water to the filter residue, decoct for half an hour, pour out, mix the two filtrates, and the daily dosage is obtained.

[0025] Example 3

[0026] Gastrodia 12g, Fried Suanzaoren 10g, Huai Niuxi 12g, Pearl Mother 10g, Fushen 20g, Fried Baishao 5g, Beichaihu 9g, Fried Jiaoshe 3g, Fried Gancao 8g, Huangqi 6g and Banxia 6g.

[0027] Stir well, then soak in 300 ml water for half an hour, then boil with high heat, then simmer for about half an hour, filter, add 300 ml water to the filter residue, simmer for half an hour, mix the two filtrates after pouring out, and you get a day's dose.

[0028] The following is an example of the composition of Example 1

[0029] 1 Data and methods

[0030] 1.1 General data

[0031] A total of 129 patients with grade 1 low-to-moderate hypertension were selected from January 2023 to March 2024 in Xiamen Hospital of Traditional Chinese Medicine, including 49 females and 80 males. According to the random number table method, they were divided into control group, Anjiang Decoction group and Anjiang Granules group, each with 43 cases. There was no statistically significant difference (P > 0.05) in gender, age and disease duration among the three groups, which was comparable. See Table 1.

[0032] Table 1 Comparison of general data of subjects in three groups

[0033]

[0034] 1.2 Diagnostic criteria

[0035] 1. 2. 1 Western medical diagnostic criteria

[0036] The diagnostic criteria for hypertension, classification and risk stratification were established according to the Guidelines for Prevention and Treatment of Hypertension in China (2018 Revised Edition). The diagnostic criteria for hypertension were as follows: under the condition of not using antihypertensive drugs, the blood pressure was measured 3 times on different days, the systolic pressure was ≥ 140 mmHg (1 mmHg ≈ 0.133 kPa) and / or the diastolic pressure was ≥ 90 mmHg. Grade 1 hypertension was defined as systolic pressure of 140-159 mmHg and / or diastolic pressure of 90-99 mmHg.

[0037] 1.2. 2 Diagnostic criteria for traditional Chinese medicine

[0038] The diagnostic criteria for the syndrome of yin deficiency and yang hyperactivity were established according to the Guidelines for Clinical Research of New Drugs for Treating Hypertension. The main symptoms were dizziness, headache, soreness, weakness, five heat, palpitations, insomnia, tinnitus, forgetfulness, red tongue, little moss, and thin and rapid pulse. Two deputy directors or above Chinese medicine doctors determined the syndrome type.

[0039] 1. 3 Inclusion and exclusion criteria

[0040] 1. 3. 1 Inclusion Criteria: ① Meets the diagnostic criteria of primary hypertension in western medicine and is stratified as low or moderate risk; ② Meets the diagnostic criteria of Yin deficiency and Yang hyperactivity syndrome; ③ Has not taken or regularly taken antihypertensive drugs within 1 month; ④ Aged 18-59 years (including boundary values); ⑤ Voluntarily participates in clinical observation and signs the informed consent form.

[0041] 1. 3. 2 Exclusion Criteria: ① Combined with severe organ damage and disease; ② Has mental, conscious, and mental abnormalities and cannot or does not want to cooperate; ③ Pregnant and lactating women; ④ Allergic or allergic to the drugs in this study; ⑤ Is receiving other clinical trials that may affect the results of this study.

[0042] 1. 4. Exclusion and Dropout Criteria

[0043] 1. 4. 1 Exclusion Criteria: ① Misplacement or misdiagnosis; ② Subjects who do not strictly complete treatment according to the research protocol; ③ Subjects who receive other treatments during the study that affect the results of this trial; ④ Subjects whose research data collection is incomplete due to various reasons.

[0044] 1. 4. 2 Dropout Criteria: ① Occurrence of serious adverse events during the study; ② Loss of follow-up due to various reasons; ③ Subjects who voluntarily withdraw.

[0045] 1. 5. Intervention Measures: Control group: Lifestyle guidance according to the relevant content in the "Guidelines for Prevention and Treatment of Hypertension in China (2018 Revised Edition)", including dietary structure adjustment, appropriate increase in exercise, weight control, smoking cessation and alcohol restriction, and psychological balance.

[0046] Anjiangfang group: On the basis of lifestyle guidance, Anjiangfang (composition: 12 g of Suanzaoren, 9 g of Tianma, 15 g of Zhenzhumu, 20 g of Fushen, 8 g of Baishao, 6 g of Chaihu, 9 g of Niuxi, 6 g of Zhike, and 5 g of Gancao) is added. All the above traditional Chinese medicines come from the Traditional Chinese Medicine Dispensary of Xiamen Hospital of Traditional Chinese Medicine and are uniformly decocted by the hospital's dispensary. One dose per day, 200 mL each time, and 1 time before afternoon nap and before bedtime.

[0047] Anjiangfang group: On the basis of lifestyle guidance, Anjiangfang (composition: 12 g of Suanzaoren, 9 g of Tianma, 15 g of Zhenzhumu, 20 g of Fushen, 8 g of Baishao, 6 g of Chaihu, 9 g of Niuxi, 6 g of Zhike, and 5 g of Gancao) is added. All the above traditional Chinese medicines come from the Traditional Chinese Medicine Dispensary of Xiamen Hospital of Traditional Chinese Medicine and are uniformly decocted by the hospital's dispensary. One dose per day, 200 mL each time, and 1 time before afternoon nap and before bedtime.

[0048] Course of treatment: Both groups are intervened for 8 weeks.

[0049] 1. 6. Evaluation Indexes and Methods of Efficacy

[0050] 1. 6. 1 Effectiveness indicators (1) Primary efficacy indicator: blood pressure reduction value after 8 weeks of treatment. The subject's clinic blood pressure was measured using an Omron medical electronic sphygmomanometer. The subject rested for 30 minutes before measurement, sat in a chair, and the midpoint of the upper arm was at the same horizontal line as the heart. The lower edge of the cuff was about 2.5 cm above the elbow pit, and the tightness was appropriate for inserting 1-2 fingers. The average value was taken from three consecutive measurements. (2) Secondary efficacy indicators: blood pressure control compliance rate after 8 weeks of treatment, TCM syndrome score, blood pressure variability (BPV), heart rate variability (HRV), neurotransmitter level, and RAAS modulator level. (3) Hypotensive efficacy evaluation criteria. Marked effect: diastolic blood pressure decreased by more than 10 mmHg and returned to normal range; or diastolic blood pressure did not return to normal range, but decreased by 20 mmHg or more (must meet one of the above conditions). Effective: diastolic blood pressure did not decrease by more than 10 mmHg, but returned to normal range; or diastolic blood pressure decreased by 10-19 mmHg compared to before treatment, but did not return to normal range; or systolic blood pressure decreased by more than 20 mmHg compared to before treatment (must meet one of the above conditions). Ineffective: did not meet the above criteria; or no effect was seen after more than 7 days of treatment.

[0051] (4) Blood pressure compliance rate evaluation criteria. Systolic blood pressure compliance rate: the proportion of subjects whose systolic blood pressure reached the target value (< 140 mmHg) after treatment. Diastolic blood pressure compliance rate: the proportion of subjects whose diastolic blood pressure reached the target value (< 90 mmHg) after treatment. Overall blood pressure compliance rate: the proportion of subjects whose overall blood pressure reached the target value (< 140 / 90 mmHg) after treatment.

[0052] (5) TCM syndrome efficacy evaluation criteria: according to the 2002 "Guidelines for Clinical Research of New Drugs of Traditional Chinese Medicine", the main symptoms were scored as 0, 2, 4, and 6 points for no symptoms, mild, moderate, and severe, respectively. The secondary symptoms were scored as 0, 1, 2, and 3 points for no symptoms, mild, moderate, and severe, respectively. The efficacy index calculation formula is: efficacy index = [(pre-treatment score - post-treatment score) / pre-treatment score] x 100%. Marked effect: efficacy index ≥ 70%. Effective: efficacy index ≥ 30% but < 70%. Ineffective: efficacy index < 30%.

[0053] 1. 6. 2 Molecular biology indicators: the levels of nitric oxide (NO) and endothelin (ET) in the subject's serum were detected using enzyme-linked immunosorbent assay.

[0054] 1. 6. 3 Safety indicators: including vital signs, blood routine, urine routine, liver function, kidney function, electrocardiogram, incidence and severity of adverse events, etc.

[0055] 1. 7 Statistical methods: SPSS 21.0 statistical software was used for data processing. Measurement data conforming to normal distribution was expressed as (x̅ ± s), and t test was used for comparison between groups; count data was expressed as percentage, and chi-square test was used for comparison between groups. Statistical test used bilateral difference test, and P < 0.05 was considered statistically significant.

[0056] 2 Results

[0057] 2. 1 Dropout and exclusion: There was no dropout in the three groups of subjects, and 1 subject in the control group was excluded due to not strictly following the lifestyle intervention program. Finally, a total of 128 subjects completed the trial, including 42 in the control group, 43 in the Anjiang Decoction group, and 43 in the Anjiang Granules group.

[0058] 2. 2 Comparison of efficacy evaluation indexes

[0059] 2. 2. 1 Comparison of blood pressure in the three groups: Compared with before treatment, the systolic and diastolic blood pressures of subjects in the control group, Anjiang Decoction group, and Anjiang Granules group were significantly reduced after treatment (P < 0.05). Compared with the control group after treatment, the systolic and diastolic blood pressures of subjects in the Anjiang Decoction and Anjiang Granules groups were significantly reduced (P < 0.05). At the same time, the systolic and diastolic blood pressures of subjects in the Anjiang Granules group were significantly reduced compared with the Anjiang Decoction group (P < 0.05). See Table 2.

[0060] 2. 2. 2 Comparison of antihypertensive efficacy in the three groups: After treatment, the total effective rate of subjects in the control group was 57.14%, the total effective rate of subjects in the Anjiang Decoction group was 90.70%, and the total effective rate of subjects in the Anjiang Granules group was 95.35%. The total effective rate of the Anjiang Granules group was significantly higher than that of the control group and the Anjiang Decoction group (P < 0.05). See Table 3.

[0061] 2. 2. 3 Comparison of blood pressure target rate in the three groups: After 8 weeks of treatment, the systolic pressure target rate, diastolic pressure target rate, and overall blood pressure target rate of patients in the Anjiang Decoction and Anjiang Granules groups were significantly higher than those in the control group (P < 0.05). At the same time, the systolic pressure target rate, diastolic pressure target rate, and overall blood pressure target rate of patients in the Anjiang Granules group were higher than those in the Anjiang Decoction group (P < 0.05). See Table 4.

[0062] Table 2 Comparison of blood pressure in the three groups before and after treatment (mmHg, x̅ ± s)

[0063]

[0064] Note: Compared with the current treatment, * P < 0. 05; compared with the control group, # P < 0. 05; compared with the Anjiang Decoction group,△ P < 0. 05.

[0065] Table 3 Comparison of antihypertensive efficacy of three groups of subjects [cases (%)]

[0066]

[0067] Note: compared with the control group, * P < 0. 05, compared with the Anjiangfang group, △ P < 0. 05.

[0068] Table 4 Comparison of blood pressure compliance rate of three groups of subjects [cases (%)]

[0069]

[0070] Note: compared with the control group, * P < 0. 05; compared with the Anjiangfang group, △ P < 0. 05.

[0071] 2.2. 4 Comparison of TCM syndrome efficacy of three groups: TCM syndrome score (see Table 5), compared with before treatment, the TCM syndrome score of patients in the control group, the Anjiangfang group and the Anjiang granule group was significantly reduced after treatment (P < 0.05). Compared with the control group after treatment, the TCM syndrome score of subjects in the Anjiang granule group decreased most significantly (P < 0.05) and the TCM syndrome score of subjects in the Anjiang granule group decreased more significantly compared with the Anjiangfang group (P < 0.05). In terms of TCM syndrome efficacy (see Table 6), the total effective rate of the Anjiang granule group was significantly higher than that of the control group and the Anjiangfang group (P < 0.05).

[0072] Table 5 Comparison of TCM syndrome scores of three groups of subjects (points, x̅ ± s)

[0073]

[0074] Note: compared with before treatment, * P < 0. 05; compared with the control group, # P < 0. 05; compared with the Anjiangfang group, △ P < 0. 05.

[0075] Table 6 Comparison of TCM syndrome efficacy of three groups of subjects [cases (%)]

[0076]

[0077] Note: compared with the control group, * P < 0. 05; compared with the Anjiangfang group, △ P < 0. 05.

[0078] 2.2. 5 Comparison of 24-hour ambulatory blood pressure BPV and 24-hour ambulatory electrocardiogram HRV in three groups: After treatment, there were significant differences in SBP-cv, DBP-cv, SDNN, SDANN, and rMSSD in the control group, the Anjiang Decoction group, and the Anjiang Granules group compared with before treatment (P < 0.05). Compared with the control group after treatment, the SBP-cv and DBP-cv in the Anjiang Decoction group and the Anjiang Granules group decreased more significantly (P < 0.05), and the SDNN, SDANN, and rMSSD increased more significantly (P < 0.05). See Table 7.

[0079] Table 7 Comparison of BPV and HRV in three groups (x̅ ± s)

[0080]

[0081] Note: Compared with before treatment in the group, * P < 0. 05; compared with the control group, # P < 0. 05

[0082] 2.2. 6 Comparison of the efficacy of neurotransmitter levels in three groups: The neurotransmitters detected in this study include glutamate (Glu) and gamma-aminobutyric acid (GABA). After treatment, the Glu levels in the three groups were significantly lower than before treatment in the group (P < 0.05), and the GABA levels in the Anjiang Decoction group and the Anjiang Granules group were significantly higher (P < 0.05). Compared with the control group after treatment, the Glu and GABA levels in the Anjiang Granules group improved most significantly (P < 0.05). Compared with the Anjiang Decoction group after treatment, the Glu and GABA levels in the Anjiang Granules group improved more significantly (P < 0.05). See Table 8.

[0083] Table 8 Comparison of Glu and GABA levels in three groups (μmol·L -1 , x̅ ± s)

[0084]

[0085] Note: Compared with before treatment in the group, * P < 0. 05; compared with the control group, # P < 0. 05; compared with the Anjiang Decoction group, △ P < 0. 05.

[0086] 2.2. 7 Comparison of three groups of RAAS modulators: The RAAS modulators detected in this study include renin (PRA), angiotensin II (Ang II), and aldosterone (ALD). After treatment, the levels of Ang II in the control group, PRA, Ang II, and ALD in the Anjiang Capsule group were significantly different from those before treatment (P < 0.05). Compared with the control group after treatment, the PRA, Ang II, and ALD levels in the Anjiang Capsule group were significantly reduced (P < 0.05). See Table 9.

[0087] Table 9 Comparison of PRA, Ang II, and ALD levels in three groups of subjects (x̅ ± s)

[0088]

[0089] Note: Compared with the group before treatment, * P < 0. 05; compared with the control group, # P < 0. 05

[0090] 2.3 Comparison of serum endothelial function factor levels in three groups: The serum endothelial function factors detected in this study include NO and ET. After treatment, the serum NO and ET levels in the control group, Anjiang Capsule group, and Anjiang Granule group were significantly different from those before treatment (P < 0.05). Compared with the control group after treatment, the NO levels in the Anjiang Capsule and Anjiang Granule groups were significantly higher (P < 0.05), and the ET levels were significantly lower (P < 0.05). See Table 10.

[0091] Table 10 Comparison of serum NO and ET levels in three groups of subjects (x̅ ± s)

[0092]

[0093] Note: Compared with the group before treatment, * P < 0. 05; compared with the control group, # P < 0. 05

[0094] 2.4 Safety evaluation: During the study, no adverse reactions occurred in the two groups of subjects. After treatment, there were no significant changes in blood routine, urine routine, liver function, kidney function, and electrocardiogram in the three groups of subjects compared with before treatment.

[0095] The above is only a preferred embodiment of the present application, and therefore cannot limit the scope of the present application. Any equivalent changes and modifications made in accordance with the scope and content of the present patent should still be within the scope of the present application.

Claims

1. A traditional Chinese medicine composition for treating grade 1 low-to-intermediate risk hypertension, characterized in that, By weight, it includes: Gastrodia elata 6-12 parts, stir-fried Ziziphus jujuba var. spinosa 9-15 parts, Achyranthes bidentata 6-12 parts, pearl powder 10-20 parts, Poria cocos 10-20 parts, stir-fried Paeonia lactiflora 5-11 parts, Bupleurum chinense 3-9 parts, stir-fried Citrus aurantium 3-9 parts, prepared Glycyrrhiza uralensis 2-8 parts, Scutellaria baicalensis 2-8 parts, and Pinellia ternata 2-8 parts.

2. The traditional Chinese medicine composition for treating grade 1 low-to-intermediate risk hypertension according to claim 1, characterized in that, By weight, it includes: 9 parts Gastrodia elata, 12 parts stir-fried Ziziphus jujuba var. spinosa, 9 parts Achyranthes bidentata, 15 parts pearl powder, 15 parts Poria cocos, 8 parts stir-fried Paeonia lactiflora, 6 parts Bupleurum chinense, 6 parts stir-fried Citrus aurantium, 5 parts prepared Glycyrrhiza uralensis, 6 parts Scutellaria baicalensis, and 6 parts Pinellia ternata.

3. The traditional Chinese medicine composition for treating grade 1 low-to-intermediate hypertension according to claim 1, characterized in that: Each dose of the traditional Chinese medicine composition is equivalent to 58g to 128g of raw materials.

4. A method for preparing a traditional Chinese medicine composition for treating grade 1 low-to-intermediate hypertension as described in claim 1, comprising the following steps: weighing each component according to the above mass ratio, and washing each raw material drug according to its characteristics; decocting the above traditional Chinese medicine composition with water to obtain a first decoction; separating the remaining portion after the first decoction, including the remaining dregs and residual liquid, and decocting again with water to obtain a second decoction; combining the first decoction and the second decoction to obtain the final product.

5. The method for preparing the traditional Chinese medicine composition according to claim 4, characterized in that: The above-mentioned Chinese herbal medicine composition should be boiled over high heat until boiling, and then simmered over low heat for 25-35 minutes.

6. The method for preparing the traditional Chinese medicine composition according to claim 4, characterized in that: The volume of the first decoction is 200-350 mL per dose; the volume of the second decoction is 200-350 mL per dose; each dose of the traditional Chinese medicine composition is equivalent to 58g-128g of raw materials.

7. Use of any traditional Chinese medicine composition according to claim 1 or 2 in the preparation of a medicament for treating grade 1 low-to-intermediate hypertension.

8. The use according to claim 7, characterized in that: The drug is an oral formulation.

9. The use according to claim 8, characterized in that: The oral preparations include mixtures, granules, tablets, pills, or capsules.

Images